More Big Pharma Players Have Access Plans For Poorer Countries
GSK Tops Access to Medicine Index Again
The notion that pharma R&D caters for western populations first and only much later are the fruits of that research made available for low-income countries is slowly but surely changing, according to a high-profile review of access to drugs.
You may also be interested in...
The “Accord for a Healthier World” pledges to provide patent-protected medicines on a not-for-profit basis in 45 lower-income nations. Pfizer, which profited most from the COVID-19 pandemic, sees the pandemic experience as a way to advance health equity.
Billions of dollars have been wiped off the value of big pharma stocks as the market finally woke up to widescale litigation concerning allegations of increased cancer risk associated with the use of ranitidine. Two companies, GSK and Sanofi, are confident that there is no link.
The French firm's lead microbiome therapy has been on clinical hold in the US for a year and continuing concerns about MaaT's 'pooling' approach (mixing donations from multiple donors) suggests the wait to restart trials will not be a short one.